165 results about "Immediate release" patented technology

A solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet. A method of making a solid oral immediate release formulation of LSD by lyophilizing a flash frozen stock solution of LSD and excipients, including a non-gelling matrix former, filler, and binder in a pre-formed mold, and forming an orally disintegrating tablet. A method of treating an individual by administering a solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet and treating the individual.

The present invention discloses modified-release bilayer tablets consisting of two layers, layer 1 consisting 500 mg sustained release metformin and layer 2 consisting 250 mg normal release metformin and 5mg / 10mg delayed-release dapagliflozin. This formulation is meticulously designed to regulate blood glucose levels effectively over an extended period. Immediate-release metformin swiftly addresses acute glucose spikes, while sustained-release metformin ensures prolonged glucose control, minimizing fluctuations throughout the day. The delayed-release dapagliflozin component allows for controlled and timed release, managing persistent hyperglycemia synergistically with metformin. By optimizing efficacy and minimizing glucose fluctuations, this innovative formulation offers a promising solution for stable glycemic control in individuals with diabetes. Present invention aims to improve patient outcomes and enhance overall quality of life by maintaining stable glucose levels and reducing the risk of complications associated with uncontrolled diabetes.

The invention belongs to the field of pharmaceutical preparations, and particularly relates to a sustained-release oral soluble film and a preparation method thereof, and the sustained-release oral soluble film comprises a sustained-release pellet core, a film forming material, a plasticizer and a flavoring agent. According to the invention, a multi-unit drug delivery system is provided, a small-particle-size film-controlled sustained-release pellet core is firstly prepared as an intermediate and then added into a film-forming material to form the oral-soluble film preparation, so that the limitation that the oral-soluble film is only applied as a quick-release preparation generally is broken through; the invention provides a slow-release oral soluble film preparation which is convenient for accurately dividing dosage, has better taste, can improve the medicine taking convenience and compliance of patients and has stable and lasting blood concentration.

The invention provides a nicotine orally disintegrating tablet with a multi-layer composite sustained-release structure and a preparation method of the nicotine orally disintegrating tablet. The nicotine orally disintegrating tablet comprises an inner layer, a middle layer and an outer layer, wherein the middle layer and the outer layer sequentially coat the inner layer from inside to outside; the outer layer comprises nicotine, instant starch and a lubricant; the middle layer comprises nicotine, ethyl cellulose, polyethylene glycol and a flow aid; the inner layer comprises the following components: nicotine nanoparticles coated with chitosan and sodium tripolyphosphate, an oral microenvironment regulator and a filling agent. According to the nicotine orally disintegrating tablet provided by the invention, due to the gradient coating structure design of the inner layer, the middle layer and the outer layer, the multi-stage accurate release of nicotine, namely early-stage quick release, middle-stage stable release and later-stage slow release, is realized, the reactions of dizziness, vomiting and the like caused by excessive release of nicotine are avoided, and the use comfort is improved. Meanwhile, the pH value of the oral cavity is adjusted, micro-ecological balance of the oral cavity is maintained, the content of volatile sulfide in breath is reduced, and breath is refreshed.

The invention provides an oral solid formulation comprising (a) a plurality of controlled release components comprising (i) a core comprising a mixture of levodopa and at least one pharmaceutically acceptable excipient, (ii) a controlled release coating surrounding the core, (iii) a muco-adhesive coating surrounding the controlled release coating and (iv) an enteric coating surrounding the muco-adhesive coating; and (b) one or more immediate release components comprising levodopa. The oral solid formulation also contains carbidopa and about 80% to 100% of the carbidopa in the oral solid formulation is present in the one or more immediate release components.

The invention is a method for treating patients with Parkinson's disease by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose “Off” time, total post dose “On” time and total post dose “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.

The present invention provides a solid, immediate- and rapid-release pharmaceutical composition with improved stability, comprising enalapril maleate and pharmaceutically acceptable excipients. Also described are the use thereof and a method for preparing the solid, immediate- and rapid-release pharmaceutical composition with improved stability, comprising enalapril maleate and pharmaceutically acceptable excipients.

A solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet. A method of making a solid oral immediate release formulation of LSD by lyophilizing a flash frozen stock solution of LSD and excipients, including a non-gelling matrix former, filler, and binder in a pre-formed mold, and forming an orally disintegrating tablet. A method of treating an individual by administering a solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet and treating the individual.

The invention is a method for treating patients with Parkinson's disease by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose “Off” time, total post dose “On” time and total post dose “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.

The invention provides a loxoprofen sodium double-release capsule micro-tablet and a preparation method of the loxoprofen sodium double-release capsule micro-tablet. Through the synergistic effect of the quick-release micro-tablet and the sustained-release micro-tablet, the quick-release micro-tablet can realize quick release and absorption, and the sustained-release micro-tablet can maintain relatively stable blood concentration for a long time. The administration frequency is reduced, the coordination of the postprandial administration requirement and the dietary habit is ensured, and the occurrence of gastrointestinal tract adverse reactions is reduced. The preparation provided by the invention conforms to the dosage form design of the hour pharmacology, can quickly take effect through administration twice every day, can maintain the blood concentration in the high-incidence time period of night diseases, avoids the disadvantage of taking medicine after meal when the night diseases attack, guarantees the sleep quality, and improves the overall treatment effect. The micro tablet is small in size and easy to swallow, and the medication compliance of patients with dysphagia is obviously improved. Through dosage form design and improvement, unmet clinical requirements are expected to be met by virtue of obvious advantages of the traditional Chinese medicine composition.

A solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet. A method of making a solid oral immediate release formulation of LSD by lyophilizing a flash frozen stock solution of LSD and excipients, including a non-gelling matrix former, filler, and binder in a pre-formed mold, and forming an orally disintegrating tablet. A method of treating an individual by administering a solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet and treating the individual.

The invention is a method for treating patients with Parkinson's disease by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose “Off” time, total post dose “On” time and total post dose “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.

The invention relates to the technical field of burn and scald treatment, in particular to an intelligent hydrogel dressing for targeted regulation and control of Mongolian medicine release. The dressing comprises a core-shell microsphere drug loading system used for realizing physical segmentation of a functional area; the dual-release system is used for realizing surface adsorption of quick-release drug nanoparticles and internal wrapping of sustained-release microspheres; a hydrogel matrix for forming a nanofiber network; and the magnetic control regulator is magnetic nanoparticles dispersed in the hydrogel matrix, and regulates the aperture of the hydrogel network through the action of an external magnetic field. According to the intelligent hydrogel dressing for targeted regulation and control of Mongolian medicine release, the Mongolian medicine compound intelligent hydrogel dressing is developed on the basis of a TRIZ innovative method; through a core-shell microsphere drug loading system and a dual release design, high drug loading capacity and accurate drug release control are synchronously realized.

The application relates to the technical field of cough-relieving medicines, and discloses a high-efficiency cough-relieving loquat particle composition which is composed of the following components in parts by weight: loquat leaf extract 30-40 parts; white front extract 10-15 parts; platycodon grandiflorum extract 6-10 parts; white mulberry bark extract 18-25 parts; stemona sessiliflora extract 7-10 parts; menthol 0.1-0.5 part; polyethylene glycol 2-5 parts; mannitol 8-12 parts; ethyl cellulose 3-6 parts; hydroxypropyl methyl cellulose 1-3 parts; phosphatidylcholine 1-3 parts; polysorbate 80 1-3 parts; cross-linked sodium carboxymethyl cellulose 4-6 parts; and sucrose 40-60 parts. The double dispersion system combining the immediate-release component and the sustained-release component is adopted, the solubility and the initial release speed of the traditional Chinese medicine extract are remarkably improved through the addition of polyethylene glycol and mannitol, and the technical effect that the drug effect appearing time is remarkably shortened is achieved. Compared with the technical scheme relying on only a single release mode in the prior art, the deficiency that the drug effect is slow and the symptoms of the patient cannot be timely relieved is solved.

The patent document discloses a dosage form featuring a unique combination of extended-release and immediate-release components of the active ingredient. This dosage form allows for high drug loading, enabling once-daily administration while providing a sustained window of effective treatment with reduced fluctuations in drug concentration. The document also discloses a method for treating neurological or psychiatric diseases or conditions in a subject.

The invention provides a melogabalin besylate composite pulse drug release preparation and a preparation method thereof, and belongs to the technical field of pharmaceutical preparations. The melogabalin besylate composite pulse drug release preparation provided by the invention comprises a composite tablet and a film coating coated on the surface of the composite tablet, wherein the composite tablet comprises a slow release layer and a pulse-quick release layer which are laminated; the sustained-release layer is formed by drug-containing sustained-release particles; the pulse-quick release layer is formed by drug-containing pulse pellets and drug-containing quick release particles; the drug-containing pulse pellet comprises a drug-containing pellet core, an isolation layer coating the surface of the drug-containing pellet core, a time-lag layer coating the surface of the isolation layer and an enteric layer coating the surface of the time-lag layer. The melogabalin besylate composite pulse drug release preparation provided by the invention can realize stable and effective release of drugs in the daytime and high-concentration release at night, and can avoid the saturated absorption problem and improve the overall bioavailability at the same time.

Disclosed herein are immediate release oral dosage forms that contain abuse-deterrent and abuse-resistant features. In particular, the disclosed dosage forms can provide deterrence of abuse by ingestion of multiple individual doses. The disclosed dosage forms can likewise provide protection from overdose in the event of accidental or intentional ingestion of multiple individual doses. The dosage forms may also exhibit abuse resistant properties when physically manipulated, and also when physically manipulated and then administered in a manner not consistent with oral dosing. The dosage forms may also exhibit abuse resistant properties when administered in a manner intended to result in administration of the esketamine in a higher than therapeutic dose.

The invention is a method for treating patients with Parkinson's disease by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose “Off” time, total post dose “On” time and total post dose “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.

The present invention relates to pharmaceutical compositions, specifically bilayer tablet formulations containing mirabegron and solifenacin succinate. The invention particularly addresses improvements in in-vitro release of solifenacin succinate in immediate release layer by improved manufacturing processes.

Provided herein are pharmaceutical formulations comprising glucokinase activator, or a prodrug, or a pharmaceutically acceptable salt, an isotope labeled analogue, a crystalline form, a hydrate, a solvate, or a diastereomeric or enantiomeric form thereof and the use thereof for treating diseases; the pharmaceutical formulations are in the form of immediate-release formulations, extended-release formulations, or combination of immediate-release formulation and extended-release formulations. The pharmaceutical formulations achieved once-a-day therapy for some diseases, in particular, type II Diabetes Mellitus with obesity. The pharmaceutical formulations exhibit sustained 24 hours of glucose-lowering effects. The pharmaceutical formulations also achieved lower Cmax, extended T1 / 2 as well as maintained similar bioavailability and increased MRT compared with commercial Dorzagliatin tablet, enhanced the pharmacology effect of restoring the glucose stimulated GLP-1 secretion in diabetes with obesity.

The invention provides a sitagliptin and metformin sustained-release pharmaceutical composition as well as a preparation method and application thereof, and relates to the technical field of sustained-release preparations. The pharmaceutical composition comprises a sustained-release tablet core and a quick-release coating layer, the sustained-release tablet core comprises an active ingredient metformin hydrochloride and a sustained-release framework material hydroxypropyl methylcellulose, and the sustained-release tablet core does not contain microcrystalline cellulose; the quick-release coating layer comprises an active component sitagliptin phosphate; the weight ratio of metformin hydrochloride to hydroxypropyl methylcellulose in the sustained release tablet core is 50: (24-27). The composition utilizes a double-layer structure to realize double-phase release of the medicine; the microcrystalline cellulose is removed, and the specific ratio of the active component to the framework material is limited, so that the moldability and ideal dissolution behavior of the preparation are ensured while the tablet weight is remarkably reduced to improve the swallowing compliance, and the technical problem that the slow-release framework function is difficult to maintain under the condition that the weight of a high-drug-loading-capacity compound preparation is greatly reduced is successfully solved.

This application discloses a mild and long-lasting antibacterial tea tree oil cleaning composition, its preparation method, and its application. The composition comprises the following raw material components by mass percentage: 1.5%~3.5% tea tree oil microcapsules; 0.8%~2.5% rosemary-clove compound extract; 0.2%~0.8% protease; 10%~30% surfactant; 2%~5.5% auxiliaries; 0.2%~1% preservative; 0.2%~0.8% pH adjuster; and the balance being deionized water. This composition achieves a long-lasting antibacterial effect after washing through multiple mechanisms, including microcapsule sustained release, immediate release, and synergistic effect with plant extracts, effectively solving the technical problems of tea tree oil's volatility, easy oxidation, and short antibacterial duration.

The application provides a sitagliptin and metformin hydrochloride sustained-release pharmaceutical composition and a preparation method and application thereof, and relates to the technical field of sustained-release preparations. The pharmaceutical composition comprises a sustained-release tablet core and a quick-release coating layer; the sustained-release tablet core comprises active ingredients metformin hydrochloride and a sustained-release matrix material hydroxypropyl methyl cellulose, and the sustained-release tablet core does not contain microcrystalline cellulose; the quick-release coating layer comprises active ingredients sitagliptin phosphate; the weight ratio of metformin hydrochloride to hydroxypropyl methyl cellulose in the sustained-release tablet core is 50:(24-27). The composition realizes double-phase release of drugs by using a double-layer structure; by removing the microcrystalline cellulose and limiting the specific ratio of active ingredients to the matrix material, the forming property of the preparation and the ideal dissolution behavior are ensured while the tablet weight is significantly reduced to improve the swallowing compliance, and the technical problem that a high drug loading compound preparation is difficult to maintain the function of the sustained-release matrix under a large amount of weight reduction is successfully solved.

The present invention relates to a pharmaceutical composition for oral administration, the pharmaceutical composition comprising: a) immediate-release granules comprising i. an active ingredient selected from the group consisting of valproic acid, semi-sodium valproic acid, sodium valproic acid, and magnesium valproic acid, and ii. a filler; and b) sustained-release pellets comprising: i. a pellet core comprising (1) an active ingredient selected from the group consisting of valproic acid, semi-sodium valproic acid, sodium valproic acid, and magnesium valproic acid, and (2) a filler; and ii. on the pellet core iii. A sustained-release pellet comprising a subcoat provided on the subcoat, the content of which is 10 to 20% by weight based on the weight of the pellet core and contains a film-forming agent, and iii. a sustained-release coating provided on the subcoat, the content of which is 25 to 100% by weight based on the weight of the pellet core coated with the subcoat and contains a film-forming agent, wherein the amount of active ingredient in the immediate-release granules accounts for 70 to 80% by weight of the total weight of active ingredients in the pharmaceutical composition, and the amount of active ingredient in the sustained-release pellets accounts for 20 to 30% by weight of the total weight of active ingredients in the pharmaceutical composition. In yet another aspect, the present invention relates to a method for producing a pharmaceutical composition and a pharmaceutical composition for use in a method of pretreatment of cancer.

The invention discloses a multi-system function regeneration factor composition as well as a preparation method and application thereof. The multi-system function regeneration factor composition is prepared from the following components in parts by mass: 0.8 to 2.4 parts of melatonin, 84 to 126 parts of nicotinamide ribose and 42 to 84 parts of resveratrol. According to the multi-system functional regeneration factor composition disclosed by the invention, through scientific proportioning and synergistic effect of melatonin, nicotinamide ribose and resveratrol, the functions of stem cells are strongly activated, proliferation of the stem cells is remarkably promoted, the stemness maintaining capability of the stem cells is improved, osteogenesis and adipogenesis differentiation potential is enhanced, and the regeneration effect of the stem cells is improved. Meanwhile, an NAD < + > metabolic pathway is activated so as to strengthen cell energy and anti-aging capability. The capsule adopts the design of combining quick-release pellets and sustained-release pellets, the quick-release part can quickly release melatonin, the local drug concentration can be increased in a short time, and stem cell activation signals can be quickly started; and the sustained release part slowly releases nicotinamide ribose and resveratrol to maintain the long-acting stability of the drug concentration, so that the effect taking speed is ensured, the action time is prolonged, and the bioavailability is greatly improved.

The invention relates to the technical field of pharmaceutical preparations, and particularly discloses a composition containing a Nicodil multi-tablet structure and capable of realizing stepped slow controlled-release drug delivery. The invention relates to a composition containing a Nicodil multi-tablet structure stepped slow controlled-release drug delivery. The composition comprises a capsule shell and at least two micro-structure drug-containing bodies with different release rates, wherein the capsule shell is filled with the micro-structure drug-containing bodies; the microstructure drug-containing body is selected from at least two of a sustained-release tablet, an enteric-coated tablet and a quick-release tablet; and the microstructure drug-containing body contains an active drug Nicodil. The composition disclosed by the invention realizes rapid and stable slow-release drug release, overcomes side effects caused by a plasma ultra-safe interval due to burst release, ensures that a plasma treatment concentration is rapidly reached, realizes slow release, remarkably reduces degradation of active components in the composition, and improves the stability of the composition.

The present invention relates to an oral extended-release dosage form of 7-methylxanthine (7-MX) or a pharmaceutically acceptable salt thereof. The dosage form is designed for twice-daily administration and provides controlled release of the active agent, achieving pharmacokinetic characteristics including sustained plasma concentrations and reduced fluctuation compared to immediate-release formulations. The invention further relates to the use of such dosage forms in the treatment of myopia, wherein the extended-release characteristics enhance therapeutic effectiveness in myopia.

A pharmaceutical formulation according to some embodiments comprises: an immediate-release part for eluting an active ingredient in a pH-independent manner; and an enteric part for eluting the active ingredient in a pH-dependent manner, wherein the active ingredient may comprise a proton pump inhibitor, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof. Some embodiments of the present invention enable immediate absorption of drugs while maintaining prolonged pharmacological efficacy.

The invention relates to the technical field of pharmaceutical preparations, and particularly discloses an arginine ibuprofen biphasic sustained release preparation and a preparation method thereof. Through a two-phase system of quick-release particles and slow-release particles, the problems that a traditional preparation takes effect slowly, is short in medicine effect and poor in taste are solved. Wherein the quick-release granules are prepared by mixing and granulating ibuprofen arginine, a filling agent, an adhesive and a natural flavoring agent, so that the effective blood concentration can be ensured to be reached within 15 minutes after the medicine is orally taken so as to quickly relieve pain, and the bad flavor of the medicine can be synchronously covered; the sustained-release granules are based on an ibuprofen arginine drug-loading core, the outer layer of the sustained-release granules is coated with a sustained-release film formed by a sustained-release agent and a plasticizer, and the effective blood concentration can be stably maintained for 6-8 hours, so that the medicine taking frequency is reduced, the sustained-release granules only need to be taken for 1-2 times every day, the medication compliance of a patient is greatly improved, and the sustained-release granules are suitable for clinical application. The traditional Chinese medicine composition is especially suitable for clinical scenes needing long-term or repeated analgesia such as chronic arthritis and postoperative pain, has excellent safety and practicability, and has a wide market application prospect.

The embodiment of the invention provides a buccal product and a preparation method thereof, the buccal product provided by the embodiment of the invention comprises a functional layer, the functional layer comprises active substances, a slow-release base material and a film-forming base material, the active substances comprise nicotine and nicotine salt, and at least part of nicotine is embedded in the slow-release base material; wherein the nicotine and the nicotine salt are compounded into an active substance, the nicotine salt can realize quick release, and the sustained-release base material is used for embedding the nicotine, so that the nicotine can be inhibited from volatilizing in the drying process and is gradually dissociated in saliva, long-acting sustained release is realized, the bioavailability is improved, the release rate of the active substance can be controlled, and the sustained-release effect of the nicotine is improved. Therefore, the effects of early-stage quick release and later-stage slow release are achieved, the volatilization loss after drying can be reduced, and the validity period is prolonged; therefore, the buccal product provided by the embodiment of the invention can effectively solve the problem that the active substances in the existing buccal product are easy to release too fast in the initial stage or insufficient in the later stage.